Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
06/2005
06/16/2005US20050131024 Antiinflammatory agents; autoimmune diseases; anticancer agents
06/16/2005US20050131009 Urea substituted imidazoquinolines
06/16/2005US20050131005 4-azasteroid derivatives as androgen receptor modulators
06/16/2005US20050131000 Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with cdk inhibitory activity
06/16/2005US20050130981 Compounds
06/16/2005US20050130965 Inhibitors of p38 kinase
06/16/2005US20050130964 e.g 8-oxa-1-thia-benzo[e]naphtho[3,2-h]azulene-2-carboxylic acid ethyl ester; rheumatoid arthritis
06/16/2005US20050130955 2-(1-isopropoxy-carbonyloxy-2-methylpropyl)-7, 8-dimethoxy-4(5H), 10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine having a solubility of 15-20 mu g/mL in a 1 wt % methyl cellulose solution at 37 degrees especially mixed with a polymer, such as methyl cellulose and/or hydroxypropylmethyl cellulose.
06/16/2005US20050130952 Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases
06/16/2005US20050130947 6alpha, 9alpha-Difluoro-17alpha-((2-furanylcarbonyl)oxy)-11beta-hydroxy-16alpha-methyl-3-oxo-androsta-1,4-diene-17beta-carbothioic acid S-fluoromethyl ester completely dissolved in a liquified hydrofluoroalkane (HFA) gas as propellant; for asthma or chronic obstructive pulmonary disease (COPD)
06/16/2005US20050130935 Combination of a beta-2-adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
06/16/2005US20050130927 For treating neoplasm, hypoproliferation, hyperproliferation, degenerative and neurodegenerative diseases, ischaemia, immune system disorder, infectious disease, or metabolic dysfunction
06/16/2005US20050130903 Therapeutic agents and methods of use thereof for the modulation of angiogenesis
06/16/2005US20050130304 Regulation of endogenous gene expression in cells using zinc finger proteins
06/16/2005US20050130242 Uses of aldose-1-epimerase (mutarotase) for diagnosis and therapy of inflammatory diseases and sepsis
06/16/2005US20050130209 Expression vector comprising nucleotide sequences coding deoxyribonuclease for use as tool in treatment and prevention of cystic fibrosis
06/16/2005US20050130145 polynucleotides which identify and encode human secreted proteins (SECP); expression vectors, host cells, antibodies, and agonists; drug screening
06/16/2005US20050130130 Killer cell activatory receptor ligand for use in diagnosis, prevention and treatment of infection, cell proliferative, autoimmune and arthritic disorders
06/16/2005US20050130127 Coronavirus-like particles comprising functionally deleted genomes
06/16/2005US20050130125 End of aids for general virology, based on profound science as protein foldings: safe vaccines, universal antimicrobial means, mad cow end
06/16/2005US20050129789 Enhance natural killer cells using plant extracts from fruits, apples
06/16/2005US20050129784 Use of a chemically stabilized chlorite solution for inhibiting an antigen-specific immune response
06/16/2005US20050129739 Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms
06/16/2005US20050129718 Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant
06/16/2005US20050129688 Monkey monoclonal antibodies specific to human B7.1 and/or B7.2 primatized forms thereof, pharmaceutical compositions containing, and use thereof as immunosuppressants
06/16/2005US20050129657 Interferon-alpha induced gene
06/16/2005US20050129625 Aerosolizing dry powder of interleukin-4 receptor with carbohydrage, lipid, buffer, peptide, protein, Group II metal, or oligopeptide excipient; small aerodynamic particle size; dispersion into gas stream to make inhalant
06/16/2005CA2857067A1 Tubulin inhibitors
06/16/2005CA2547791A1 Therapeutics use of pyridinium compounds to modulate naadp activity
06/16/2005CA2547651A1 Anti-inflammatory agents
06/16/2005CA2547008A1 New class of gamma delta t cells activators and use thereof
06/16/2005CA2546784A1 Glycomimetic antagonists for both e- and p-selectins
06/16/2005CA2545582A1 5-(benz-(z)-ylidene)-thiazolidin-4-one derivatives as immunosuppressant agents
06/16/2005CA2545425A1 Azole-based kinase inhibitors
06/16/2005CA2545422A1 Tubulin inhibitors
06/15/2005EP1541675A2 Hybrid cells obtainable from antigen presenting cells
06/15/2005EP1541673A1 Novel probiotics for pet food applications
06/15/2005EP1541672A1 Composition for promoting the proliferation of lactobacillus casei subsp. casei
06/15/2005EP1541583A1 Non-t cell binding peptides and their uses
06/15/2005EP1541580A1 Sulfotransferase inhibitors
06/15/2005EP1541576A1 Furoisoquinoline derivative and use thereof
06/15/2005EP1541574A1 Triazaspiro 5.5 undecane derivatives and drugs comprisi ng the same as the active ingredient
06/15/2005EP1541573A1 Novel crystals of triazaspiro 5.5 undecane derivative
06/15/2005EP1541571A1 Bicyclic unsaturated tertiary amine compound
06/15/2005EP1541563A1 Ccr4 antagonist and medicinal use thereof
06/15/2005EP1541562A1 Novel uracil derivatives and medicinal use thereof
06/15/2005EP1541558A1 Heterocyclic compound having hiv integrase inhibitory activity
06/15/2005EP1541170A1 Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
06/15/2005EP1541167A1 Antiallergic agent
06/15/2005EP1541149A1 Phosphodiesterase inhibitor
06/15/2005EP1539978A1 Method of isolating biologically active fraction containing clinically acceptable native slipopolysaccharides obtained from bacteria producing endotoxic lipopolysaccharides
06/15/2005EP1539941A2 Adzymes and uses thereof
06/15/2005EP1539933A2 Methods of organ regeneration
06/15/2005EP1539927A1 Probiotic bacterium: lactobacillus fermentum
06/15/2005EP1539796A1 Anti-inflammatory or anti-allergic androstane complexes
06/15/2005EP1539783A1 Inhibitors of nucleoside phosphorylases and nucleosidases
06/15/2005EP1539769A1 Bicyclic heteroaromatic compounds as kinase inhibitors
06/15/2005EP1539763A1 Azaindole kinase inhibitors
06/15/2005EP1539759A1 Use of and some novel imidazopyridines
06/15/2005EP1539758A1 Substituted pyrrolopyridines
06/15/2005EP1539757A1 Substituted pyrrolopyridines
06/15/2005EP1539752A1 Preparation of 1h-imidazo 4,5-c quinolin-4-amines via novel 1h-imidazo 4,5-c quinolin-4-cyano and 1h-imida zo 4,5-c quinolin-4-carboxamide intermediates
06/15/2005EP1539742A1 Indole derivatives useful as histamine h3 antagonists
06/15/2005EP1539741A1 2-thio-substituted imidazole derivatives and their use in pharmaceutics
06/15/2005EP1539732A1 Novel compounds
06/15/2005EP1539727A2 Compounds, compositions, and methods
06/15/2005EP1539723A1 Novel use of benzothiazole derivatives
06/15/2005EP1539714A2 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors
06/15/2005EP1539713A1 Pyrimidine derivatives as modulators of chemokine receptor activity
06/15/2005EP1539701A1 Caspase inhibitors and uses thereof
06/15/2005EP1539696A2 Process for preparing quinolin antibiotic intermediates
06/15/2005EP1539695A1 N-4-piperidinyl compounds as ccr5 modulators
06/15/2005EP1539693A1 Cannabinoid receptor agonists
06/15/2005EP1539685A1 Mcp-1 receptor antagonists and method of use thereof
06/15/2005EP1539683A2 Phenol derivatives and their use as rotamase inhibitors
06/15/2005EP1539679A2 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
06/15/2005EP1539678A1 3,4-di-substituted cyclobutene-1, 2-diones as cxc-chemokine receptor ligands
06/15/2005EP1539674A1 Amino-propanol derivatives
06/15/2005EP1539662A1 Cannabinoid receptor ligands
06/15/2005EP1539284A2 Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols
06/15/2005EP1539241A2 Method of controlling pharmacokinetics of immunomodulatory compounds
06/15/2005EP1539236A2 Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof
06/15/2005EP1539216A2 Labelled somatostatin analogs backbone cyclized through metal complexation
06/15/2005EP1539180A2 Compounds, compositions, and methods
06/15/2005EP1539170A2 Stabilized formulations of alpha adrenergic receptor antagonists and uses thereof
06/15/2005EP1539161A1 Novel salt and polymorphs of desloratadine hemifumarate
06/15/2005EP1539160A1 Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders
06/15/2005EP1539159A1 Sulphonylpiperidine derivatives containing an aryl or heteroaryl group for use as matrix metalloproteinase inhibitors
06/15/2005EP1450808B1 Quinazoline derivatives for the treatment of t cell mediated diseases
06/15/2005EP1373240B1 Retinoid x receptor modulators
06/15/2005EP1325007B1 Hexahydropyrazino[1'2':1,6]-pyrido[3,4-b]indole-1,4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction
06/15/2005EP1278530B1 Chemical modification of mammalian urine
06/15/2005EP1251841B1 Camphor aqueous solution for treating degenerative or autoimmune diseases and as immunomodulatory agent
06/15/2005EP1248836B1 Method for preparing vaccines by using hybrid cells
06/15/2005EP1248785B1 Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
06/15/2005EP1232139B1 Nervonic acid derivatives, their preparation and use
06/15/2005EP1126843A4 Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
06/15/2005EP1104412B1 Tace inhibitors
06/15/2005EP1066050B1 Application of hsp70 proteins
06/15/2005EP1064277B1 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
1 ... 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 ... 1172